Management of Sciatica in Seniors

Contraindications and Risks

The Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement contraindicates tizanidine in elderly patients due to significant sedative and hypotensive effects 1, 2
Tizanidine causes dose-dependent sedation, drowsiness, dizziness, ataxia, and lethargy, similar to cyclobenzaprine 1, 2
Both medications carry similar CNS depression risks, with skeletal muscle relaxants associated with higher rates of central nervous system adverse events (RR 2.04) compared to placebo 3
Tizanidine is associated with additional cardiovascular risks, including significant hypotension and bradycardia, particularly dangerous in elderly patients 1, 2

One higher-quality trial found no difference between tizanidine and placebo for sciatica, making it an inappropriate choice for this indication 3
Muscle relaxants have limited evidence for sciatica pain, with most trials excluding older patients and focusing on acute low back pain rather than radicular symptoms 3

The American Geriatrics Society recommends discontinuing cyclobenzaprine entirely rather than switching to another muscle relaxant, due to the lack of evidence for chronic use and significant adverse effect burden 6
If discontinuing after prolonged use, taper cyclobenzaprine gradually over 2-3 weeks to prevent withdrawal symptoms 5, 6
For mild sciatica in seniors, focus on non-pharmacologic approaches, physical therapy, and consider gabapentin or topiramate if pharmacologic management is needed 3
The American Geriatrics Society Beers Criteria identifies muscle relaxants as potentially inappropriate medications for older adults, due to significant sedation risk 6